Company Description
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP).
It also develops efgartigimod for the treatment of seronegative and ocular gMG, thyroid eye diseases, ITP, myositis, Sjögren’s disease, lupus nephropathy, systemic sclerosis, antibody-mediated rejection, and autoimmune encephalitis; empasiprubart for multifocal motor neuropath, CIDP, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome, amyotrophic lateral sclerosis, and spinal muscular atrophy.
In addition, the company is also developing ARGX-119, a MuSK agonist to treat congenital myasthenic syndromes and amyotrophic lateral sclerosis; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121 and ARGX 220 that targets the immune system; ARGX-213, which targets FcRn; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115.
It has strategic collaborations with OncoVerity, Inc, LEO Pharma A/S, Zai Lab Limited, AbbVie, Inc., Elektrofi, Genmab SE, Chugai Pharmaceutical Co., Ltd., Clayton Foundation, Halozyme Therapeutics, Inc., AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Lonza Sales AG, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, and IQVIA Ltd. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
| Country | Netherlands |
| Founded | 2008 |
| IPO Date | May 18, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,599 |
| CEO | Timothy Van Hauwermeiren |
Contact Details
Address: Laarderhoogtweg 25 Amsterdam, 1101 EB Netherlands | |
| Phone | 31 10 703 8441 |
| Website | argenx.com |
Stock Details
| Ticker Symbol | ARGX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001697862 |
| CUSIP Number | 04016X101 |
| ISIN Number | US04016X1019 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Timothy Van Hauwermeiren EMBA, M.Sc. | Co-Founder, Chief Executive Officer and Executive Director |
| Karl Gubitz | Chief Financial Officer |
| Karen Massey | Chief Operating Officer |
| Dr. Peter Ulrichts | Chief Scientific Officer |
| Malini Moorthy | General Counsel |
| Arjen Lemmen M.Sc. | Vice President of Corporate Development and Strategy |
| Andria Wilk | Global Head of Quality |
| Dr. Luc Truyen | Chief Medical Officer |
| Filip Borgions | Vice President and Global Head of Technical Operations |
| Beth DelGiacco | Vice President and Global Head of Corporate Communications and Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 20, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Mar 20, 2025 | 6-K | Report of foreign issuer |
| Mar 7, 2025 | 6-K | Report of foreign issuer |
| Feb 27, 2025 | 6-K | Report of foreign issuer |
| Feb 12, 2025 | SCHEDULE 13G/A | Filing |
| Jan 13, 2025 | 6-K | Report of foreign issuer |
| Dec 27, 2024 | 6-K | Report of foreign issuer |
| Nov 20, 2024 | 6-K | Report of foreign issuer |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |